

IN THE CLAIMS

1-43. (cancelled)

44. (previously presented) A method of transplantation of cells, which method comprises the administration of a therapeutically-effective amount of melagatran, or a pharmaceutically-acceptable derivative thereof, to a patient about to be, being, or having been, subjected to such transplantation.


45. (previously presented) A method as claimed in Claim 44, wherein the cells are insulin-producing cells or precursors thereof.

46. (previously presented) A method as claimed in Claim 44, wherein the cells are islets of Langerhans.

47. (previously presented) A method as claimed in Claim 44, wherein the cells are precursors of insulin-producing cells which are stem cells.

48. (previously presented) A method as claimed in any one of Claims 44 to 46, wherein the derivative of melagatran is a prodrug of melagatran.

49. (previously presented) A method as claimed in any one of Claims 44 to 46, wherein the derivative of melagatran is a prodrug of the formula



wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amidino hydrogens in Pab.

50. (previously presented) A method as claimed in Claim 49, wherein R^1 represents methyl, ethyl, *n*-propyl, *i*-propyl or *t*-butyl.


51. (previously presented) A method as claimed in Claim 49, wherein R^1 represents ethyl.

52. (previously presented) A method of engrafting islets of Langerhans, which method comprises administering a therapeutically-effective amount of melagatran, or a pharmaceutically-acceptable derivative thereof, to a patient about to be, being, or having been, subjected to transplantation of such islets.

53. (previously presented) A method as claimed in Claim 52, wherein the islets engraft in the liver.

54. (previously presented) A method as claimed in Claims 52 or Claim 53, wherein the derivative of melagatran is a prodrug of melagatran.

55. (previously presented) A method as claimed in Claims 52 or Claim 53, wherein the derivative of melagatran is a prodrug of the formula



wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amidino hydrogens in Pab.

56. (previously presented) A method as claimed in Claim 55, wherein R^1 represents methyl, ethyl, *n*-propyl, *i*-propyl or *t*-butyl.


57. (previously presented) A method as claimed in Claim 55, wherein R^1 represents ethyl.

58-62. (cancelled)

63. (previously presented) A method of treatment of instant blood-mediated inflammatory reaction, which method comprises administering a therapeutically-effective amount of melagatran, or a pharmaceutically-acceptable derivative thereof, to a patient in need of such treatment.

64. (previously presented) A method as claimed in Claim 63, wherein the derivative of melagatran is a prodrug of melagatran.

65. (previously presented) A method as claimed in Claim 63, wherein the derivative of melagatran is a prodrug of the formula



wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amidino hydrogens in Pab.

66. (previously presented) A method as claimed in Claim 63, wherein R^1 represents methyl, ethyl, *n*-propyl, *i*-propyl or *t*-butyl.

67. (previously presented) A method as claimed in Claim 63, wherein R^1 represents ethyl.

68-77. (cancelled)